CompletedNCT02493777
HLD200 for ADHD Symptoms in Children Ages 6 to 12
About this title
Read the official source — NCT02493777Medication studyAges 6–12United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- Newport Beach and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 125
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT02493777
- Official title
Show the full official title
Ph 3 Multicenter OL Treatment-optimized RDBPC Forced-withdrawal, Parallel Grp Study to Evaluate Safety & Efficacy of Evening Dosed HLD200, a Novel DR/ER Formulation (DELEXIS) of MPH HCl in Children Aged 6-12 With ADHD in Classroom Setting
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Newport Beach · Bradenton · Maitland
4 more locations
- Marshfield
- Las Vegas
- Houston
- Lubbock
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Ironshore Pharmaceuticals and Development, Inc.
Did this study involve medication?
Yes. The study involved medication, including HLD200 methylphenidate hydrochloride (MPH) Capsules and Placebo.
Who was this study for?
Listed age limits: 6 years to 12 years.
